Cygnus Sizzles In June; Stock Rises 77% On Heels Of Diabetes Conference
This article was originally published in The Gray Sheet
Executive Summary
The stock prices of diabetes product manufacturers Cygnus and MiniMed headed in opposite directions in the aftermath of the June 9-13 annual meeting of the American Diabetes Association.
You may also be interested in...
NACB Diabetes Guidelines Cautious On Less-Invasive Glucose Monitoring
"Routine" minimally invasive glucose sensing with Cygnus' GlucoWatch Biographer and MiniMed's CGMS continuous glucose monitor system is not recommended by the National Academy of Clinical Biochemistry (NACB) in a recent draft of the group's diabetes management guidelines.
NACB Diabetes Guidelines Cautious On Less-Invasive Glucose Monitoring
"Routine" minimally invasive glucose sensing with Cygnus' GlucoWatch Biographer and MiniMed's CGMS continuous glucose monitor system is not recommended by the National Academy of Clinical Biochemistry (NACB) in a recent draft of the group's diabetes management guidelines.
Stryker Licenses ArthroCare Coblation Technology Following Serfas Launch
Stryker Corp. agreed to license ArthroCare's Coblation radiofrequency arthroscopy technology just days after its mid-June launch of the competing Serfas arthroscopy product in order to head-off a patent infringement suit, ArthroCare says.